Loading the company…
Loading the company…
In 2025, Okami Medical reported engagement with 245 surgeons and other clinicians in the states MedaRep covers, worth $250K in consulting, speaking, meals and travel for its device products, the most in Georgia ($158K to 6). Royalties are left out.
Spend tied to a procedure counts the payments whose product names it. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing.Top states by spend: Georgia ($158K, 6 engaged), New York ($30K, 18 engaged), California ($15K, 25 engaged), North Carolina ($14K, 21 engaged), Texas ($9,984, 26 engaged).
In the last ten years FDA made 5 decisions for Okami Medical (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2026 (2). The latest was on 2026-10-06.
| Family | Decisions on record |
|---|---|
| Tumor & fibroid embolization | 5 |
| Okami Medical LOBO Vascular Occlusion System |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Okami Medical.